Laurus Labs shares drop on weak quarter | |
Laurus Labs Ltd faced a significant drop in its stock price, hitting a lower circuit during Thursday’s trading session. The pharmaceutical company reported a challenging performance in the December 2023 quarter, leading to mixed reviews by brokerage firms. The net profit for the quarter was 23.84 crore, marking an 88.5% YoY decline, primarily driven by a 67% YoY fall in the CDMO-synthesis business. In the same period the previous year, the company had reported a bottom line of 203.06 crore. Revenue also witnessed a substantial decline, falling 22.6% YoY to Rs 1,195 crore, and the Ebitda for the December 2023 quarter dropped 55% YoY to Rs 181 crore. The Ebitda margin for Q3FY24 was 15.3%, remaining below the 20% mark over the last three quarters. For more details please visit our website - https://www.medhealthinsight.com/new-soundboard-review-pricing-is-not-always-the-only-criteria-2-11-2-33/ ![]() | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: New York Target City : New York City Last Update : Sep 08, 2025 7:33 AM Number of Views: 59 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |